I-131 Tositumomab
Showing 1 - 25 of >10,000
Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)
Active, not recruiting
- Multiple Myeloma
- Iodine I 131 Tositumomab
-
Ann Arbor, MichiganUniversity of Michigan
Mar 16, 2022
Follicular Lymphoma Trial in Chicago (Bortezomib and Tositumomab I-131)
Terminated
- Follicular Lymphoma
- Bortezomib and Tositumomab I-131
-
Chicago, IllinoisRush University Medical Center
Oct 6, 2021
Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)
Active, not recruiting
- Mantle Cell Lymphoma
- R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
-
Basking Ridge, New Jersey
- +4 more
Dec 1, 2022
Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Edmonton ([131]I-IAZA)
Withdrawn
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
-
Edmonton, Alberta, CanadaCross Cancer Institute
Jul 7, 2022
Lymphoma, Mantle-Cell Trial (Tositumomab and Iodine I 131 Tositumomab followed by CHOP)
Completed
- Lymphoma, Mantle-Cell
- Tositumomab and Iodine I 131 Tositumomab followed by CHOP
- (no location specified)
Nov 19, 2019
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,
Recruiting
- Waldenstrom Macroglobulinemia
- +8 more
- Iopofosine I 131 single dose
- +2 more
-
Redlands, California
- +42 more
Dec 30, 2022
Neuroblastoma, Childhood Metastatic Pheochromocytoma Trial in Philadelphia (131 I-Metaiodobenzylguanidine (131 I-MIBG), 131
Available
- Neuroblastoma
- Childhood Metastatic Pheochromocytoma
- 131 I-Metaiodobenzylguanidine (131 I-MIBG)
- 131 I-MIBG
-
Philadelphia, PennsylvaniaThe Children's Hospital of Philadelphia
Jul 11, 2022
Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)
Not yet recruiting
- Thyroid Cancer
- +5 more
- Selpercatinib
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Dec 20, 2022
Renal Tracer Elimination in Thyroid Cancer Patients Treated With
Completed
- Thyroid Carcinoma
-
Jena, Thüringen, GermanyUniversity Hospital Jena
Dec 15, 2022
Thyroid Cancer Trial in Bialystok (metformin, Radioactive iodine (I-131))
Not yet recruiting
- Thyroid Cancer
- metformin
- Radioactive iodine (I-131)
-
Bialystok, PolandDepartment of Endocrinology, Diabetology and Internal Medicine,
Jul 26, 2022
Thyroid Cancer Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (drug, radiation,
Recruiting
- Thyroid Cancer
- Thyrogen
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 28, 2023
Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin Trial in United States (Autologous transplantation
Completed
- Lymphoma, B-Cell
- +2 more
- Autologous transplantation using rituxan/BEAM
- Autologous transplantation using Bexxar/BEAM
-
New Haven, Connecticut
- +35 more
Oct 21, 2021
Thyroid Cancer Trial in New York (131 I-iodine (131-I), 124 I-iodine (124-I))
Active, not recruiting
- Thyroid Cancer
- 131 I-iodine (131-I), 124 I-iodine (124-I)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 1, 2022
Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))
Completed
- Kidney Cancer
- Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)
Not yet recruiting
- HER2-positive Breast Cancer
- 68Ga/131I-SGMIB-5F7
-
Shanghai, ChinaHuashan Hospital
Aug 1, 2023
B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)
Recruiting
- B-ALL
- +10 more
- 131-I Apamistamab
- CAR T-cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 7, 2022
High-Grade Glioma Trial in New York, Houston, Madison (CLR 131)
Not yet recruiting
- High-Grade Glioma
- CLR 131
-
New York, New York
- +2 more
Nov 3, 2022
Differentiated Thyroid Cancer Trial in Leiden (rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry)
Recruiting
- Differentiated Thyroid Cancer
- rhTSH-stimulated I-124 dosimetry
- Intra-therapeutic I-131 dosimetry
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Apr 8, 2022
Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),
Recruiting
- Melanoma
- [131I]ICF01012 (therapeutic dose level 1)
- +3 more
-
Clermont-Ferrand, France
- +1 more
Jan 27, 2022
Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism Trial in Arnhem,
Recruiting
- Thyroid Nodule, Toxic or With Hyperthyroidism
- +5 more
- Radiofrequency ablation
- Radioactive iodine
-
Arnhem, Gelderland, Netherlands
- +1 more
Dec 2, 2021
Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)
No longer available
- Relapsed Neuroblastoma
- Metastatic Pheochromocytoma
- 131 I-Metaiodobenzylguanidine
- +2 more
-
Dallas, TexasThe University of Texas Southwestern Medical Center
Apr 13, 2022
Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)
Active, not recruiting
- Brain and Central Nervous System Tumors
- +9 more
- DNA analysis
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 28, 2021
DIPG Trial (131I-Omburtamab, Convention Enhanced Delivery)
Not yet recruiting
- DIPG
- 131I-Omburtamab
- Convention Enhanced Delivery
- (no location specified)
Feb 7, 2022
CNS/Leptomeningeal Tumors Trial in New York (131I-omburtamab)
Available
- Central Nervous System/Leptomeningeal Neoplasms
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 15, 2022